Beta Drugs Limited — Others, 13-11-2024: Shareholders meeting

Beta Drugs Ltd. held an Extraordinary General Meeting where all resolutions were unanimously approved by shareholders. The key resolutions included an increase in authorized share capital, issuance of equity shares and compulsory convertible debentures on a preferential basis, and special rights granted to HealthQuad Fund II and Inti Capital VCC. With strong voting support from both promoters and the public, these decisions signal strategic growth and potential capital infusion, which could enhance the company's financial flexibility. This positive outcome may bolster investor sentiment by indicating robust governance and future growth opportunities.